<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29463" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Statin Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khare</surname>
            <given-names>Swapnil</given-names>
          </name>
          <aff>Indiana University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Talati</surname>
            <given-names>Raja</given-names>
          </name>
          <aff>St.Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Swapnil Khare declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raja Talati declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29463.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Statin medications are used in the management of hypercholesteremia. Statins are inhibitors of hydroxymethylglutaryl-CoA reductase enzyme and lower total cholesterol, low-density lipoprotein (LDL), and triglyceride concentrations. The FDA-approved statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, and pitavastatin. Individuals&#x000a0;at high risk for atherosclerotic cardiovascular disease require more aggressive management strategies, including higher-intensity statin therapy. Participating clinicians&#x000a0;review the mechanisms of action, dosing protocols, clinical toxicology, potential drug interactions, pharmacokinetics, and monitoring strategies pertinent to healthcare professionals in managing hypocholesteremia. The utility&#x000a0;of coronary artery calcium scoring in situations of uncertainty is emphasized.&#x000a0;This activity informs the interprofessional team on the best prescribing guidelines for statins.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the appropriate candidates for statin therapy based on established guidelines and individual patient risk factors.</p></list-item><list-item><p>Screen lipid profile assessments and cardiovascular risk evaluations to determine the need for statin therapy in eligible patients.</p></list-item><list-item><p>Select the most appropriate statin and dosage regimen based on patient preferences, comorbidities, and drug-drug interactions.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve outcomes and treatment efficacy for patients who benefit from statin medications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29463&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29463">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29463.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, lower total cholesterol, low-density lipoprotein (LDL), and triglyceride concentrations while increasing high-density lipoprotein (HDL) concentrations. FDA-approved statins include atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin and pitavastatin.<xref ref-type="bibr" rid="article-29463.r1">[1]</xref>&#x000a0;Clinicians have long used statin medications to treat hypercholesterolemia, hyperlipoproteinemia, and hypertriglyceridemia as an adjunct to diet and exercise. These agents are primarily used for primary and secondary prevention of coronary artery disease. The approved FDA indications vary slightly between the medications in this class.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperlipidemia and mixed dyslipidemia<xref ref-type="bibr" rid="article-29463.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia)<xref ref-type="bibr" rid="article-29463.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypertriglyceridemia<xref ref-type="bibr" rid="article-29463.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Atherosclerosis<xref ref-type="bibr" rid="article-29463.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Primary prevention of&#x000a0;ASCVD (atherosclerotic cardiovascular disease)<xref ref-type="bibr" rid="article-29463.r6">[6]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Secondary prevention in patients with clinical ASCVD<xref ref-type="bibr" rid="article-29463.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric patients with familial hypercholesterolemia<xref ref-type="bibr" rid="article-29463.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adult patients with homozygous familial hypercholesterolemia<xref ref-type="bibr" rid="article-29463.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nonalcoholic&#x000a0;fatty liver disease<xref ref-type="bibr" rid="article-29463.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cardiac allograft vasculopathy progression<xref ref-type="bibr" rid="article-29463.r11">[11]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prevention of&#x000a0;contrast-induced acute kidney injury<xref ref-type="bibr" rid="article-29463.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29463.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Statins are a selective, competitive inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase, the enzyme responsible for converting HMG-CoA to mevalonate in the cholesterol synthesis pathway. By reducing hepatic cholesterol synthesis, an upregulation of LDL receptors and increased hepatic uptake of LDL-cholesterol from the circulation occurs. Statin treatment reduces the hepatic production rate of apo B100 containing lipoproteins, leading to a decrease in both cholesterol and triglyceride concentrations. Drug responses may also differ according to genetic factors, such as the ATP binding cassette G2, lipoprotein(a), and apo E genes [32]. The RhoA gene may play an important role in statin's LDL-C response.<xref ref-type="bibr" rid="article-29463.r13">[13]</xref></p>
        <p>HMG CoA reductase inhibitors have pleiotropic effects. Statins inhibit the synthesis of isoprenoid intermediates required for activating intracellular or signaling proteins (Ras, Rho, Rab, Rac, Ral, or Rap). Consequently, statins have anti-inflammatory, antioxidant, antiproliferative, and immunomodulatory effects. In addition, they promote plaque stability and prevent platelet aggregation. This pleiotropic effect is the class effect of statins. The COSMOS (coronary atherosclerosis study measuring the effects of rosuvastatin using intravascular ultrasound in Japanese subjects) trial results indicated that patients treated with rosuvastatin had a substantial decrease in plaque volume independent of LDL-C reduction.<xref ref-type="bibr" rid="article-29463.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Absorption is faster for lipophilic drugs like atorvastatin, simvastatin, fluvastatin, pitavastatin, and lovastatin than hydrophilic statins like rosuvastatin or pravastatin. Atorvastatin is completely absorbed after oral administration, but atorvastatin undergoes extensive first-pass metabolism; the bioavailability is about 12%. The bioavailability of pitavastatin is highest (&#x0003e;60%), followed by rosuvastatin (20%), while simvastatin has &#x0003c;5% bioavailability.<xref ref-type="bibr" rid="article-29463.r15">[15]</xref>&#x000a0;Simvastatin and lovastatin are prodrugs converted to an active form by hydrolysis.<xref ref-type="bibr" rid="article-29463.r16">[16]</xref></p>
        <p><bold>Distribution: </bold>Protein binding affects drug distribution and the pharmacological efficacy of drugs because only the unbound or free drug can elicit targeted effects. All statins have high plasma protein binding (PPB) except pravastatin (PPB ~50%). Lipophilic statins can penetrate cells by passive diffusion and are widely distributed in different tissues. Hydrophilic statins pravastatin and rosuvastatin are attached to the polar surface of the cell membrane and require protein transporters to inhibit the HMG-CoA reductase.<xref ref-type="bibr" rid="article-29463.r17">[17]</xref></p>
        <p><bold>Metabolism: </bold>CYP3A4 plays a crucial role in the metabolism of atorvastatin, lovastatin, and simvastatin. CYP2C9 metabolizes fluvastatin. Rosuvastatin is metabolized to a lesser degree by CYP2C9 and CYP2C19. OATPB1 (organic anion-transporting polyprotein) plays a role in eliminating atorvastatin, rosuvastatin, simvastatin, pitavastatin, and pravastatin, while OATPB3 is involved in the elimination of rosuvastatin, fluvastatin, and pravastatin. Atorvastatin and lovastatin are both substrates and inhibitors of P-gp (permeability glycoprotein).<xref ref-type="bibr" rid="article-29463.r18">[18]</xref></p>
        <p><bold>Excretion: </bold>Statins are extensively metabolized, and the amount of statin excreted in its unchanged form through renal elimination is comparatively less. Rosuvastatin does not undergo extensive metabolism and is primarily excreted unchanged in urine and feces. Fluvastatin, lovastatin, pravastatin, and simvastatin have a relatively short half-life. These drugs should be administered in the evening or as an extended-release formulation (for fluvastatin or lovastatin) to maximize&#x000a0;their efficacy. In contrast, atorvastatin and rosuvastatin have longer half-lives and can be administered at any time of the day. HMG-CoA reductase inhibitors are excreted into bile and feces.<xref ref-type="bibr" rid="article-29463.r19">[19]</xref></p>
      </sec>
      <sec id="article-29463.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <p>Statins medications are available in oral formulations.&#x000a0;</p>
        <p>
<bold>Strength</bold>
</p>
        <p>According to the American Heart Association and American College of Cardiology (AHA/ACC) guidelines, statins are classified into high-intensity, moderate-intensity, and low-intensity statins based on estimated LDL reductions.<xref ref-type="bibr" rid="article-29463.r20">[20]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>High-intensity statin (LDL-C lowering &#x0003e; 50%): rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg, atorvastatin 80 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Moderate-intensity statin (LDL-C lowering&#x000a0;30% to 49%): atorvastatin 10 mg, atorvastatin 20 mg, rosuvastatin&#x000a0;5 mg, rosuvastatin&#x000a0;10 mg, simvastatin 20 mg, simvastatin 40 mg,&#x000a0;pravastatin 40 mg, pravastatin 80 mg, lovastatin 40 mg, lovastatin 80 mg, fluvastatin XL 80 mg, fluvastatin 40 mg BID, pitavastatin 1 mg to 4 mg</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Low-intensity statin (LDL-C lowering &#x0003c; 30%): simvastatin 10 mg, pravastatin 20 mg, pravastatin 10 mg, lovastatin 20 mg, fluvastatin 20 mg, fluvastatin 40 mg.<xref ref-type="bibr" rid="article-29463.r21">[21]</xref><xref ref-type="bibr" rid="article-29463.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Statin&#x000a0;medications can be&#x000a0;ingested with or without&#x000a0;food. Grapefruit&#x000a0;juice should&#x000a0;be avoided with some statins to minimize CYP3A4 interactions that could increase serum concentrations.&#x000a0;Due to the diurnal variation in hepatic cholesterol synthesis, synthesis is highest in the early morning. An evening administration is the recommended dosing approach for fluvastatin, lovastatin, pravastatin, and simvastatin.<xref ref-type="bibr" rid="article-29463.r23">[23]</xref>&#x000a0;Atorvastatin, pitavastatin, and rosuvastatin dosing&#x000a0;do not require morning or evening administration,&#x000a0;but their administration should be at the same time of day.</p>
        <p>Patients with severe primary hypercholesterolemia (LDL-C &#x02265; 190 mg/dL) have a high risk of atherosclerotic cardiovascular disease (ASCVD); high-intensity&#x000a0;statin&#x000a0;therapy is recommended.<xref ref-type="bibr" rid="article-29463.r24">[24]</xref></p>
        <p>For young adults between 20 to 39 years, consider statin therapy in&#x000a0;high-risk patients (family history of premature CAD and very high LDL-C &#x02265;160 mg/dL).&#x000a0;Patients between 40 and 75 years of age with diabetes are at intermediate or high risk of future ASCVD, and moderate-intensity statin is recommended.&#x000a0;Patients between&#x000a0;40 to 75 years of age with diabetes-specific risk factors (&#x02265; 10 years for T2DM or &#x02265;20 years for type 1&#x000a0;DM or albuminuria,&#x000a0;retinopathy, neuropathy, eGFR&#x0003c;60 mL/min/1.73 m&#x000b2; or ankle-brachial index &#x0003c;0.9) are recommended high-intensity statin therapy.&#x000a0;Consider treatment with a&#x000a0;high-intensity statin for patients between 40 to 75 years of age with ASCVD &#x0003e; 20% (high risk) over&#x000a0;10 years.</p>
        <p>Consider treatment with a&#x000a0;moderate-intensity statin for patients between 40 to 75 years of age with ASCVD &#x02265;&#x000a0;7.5 to &#x0003c; 20% (moderate risk) over&#x000a0;10 years.&#x000a0;Consider treatment with a moderate-intensity statin for patients between 40 to 75 years of age with ASCVD 5% to &#x0003c; 7.5% (high risk) over&#x000a0;10 years if risk&#x000a0;factors are present.&#x000a0;Risk&#x000a0;factors&#x000a0;include: a family history of premature ASCVD, persistently elevated LDL-C&#x0003e;160 mg/dl, metabolic syndrome, chronic kidney disease, chronic inflammatory conditions (psoriasis, RA, or HIV), history of premature menopause (before age 40 years), preeclampsia, high-risk race or ethnicity (South Asian ancestry), lipids or biomarkers (elevated primary hypertriglyceridemia &#x02265; 175 mg/dL), hs-CRP (&#x02265; 2.0 mg/L),&#x000a0;Lp(a) &#x02265; 50 mg/dL,&#x000a0;apoB (&#x02265;130 mg/dL), ankle branchial index &#x0003c;0.9.<xref ref-type="bibr" rid="article-29463.r25">[25]</xref></p>
        <p>In adults&#x000a0;with intermediate risk (&#x02265;7.5% to &#x0003c;20%) or adults at borderline risk (5% to &#x0003c; 7.5%), measure coronary artery calcium (CAC) levels.</p>
        <list list-type="bullet">
          <list-item>
            <p>If CAC is 0 Agatston units, no statin is required unless there is a history of diabetes mellitus, a family history of premature congestive heart failure (CHD), or cigarette smoking is present.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If CAC is 1 to 99 Agatston units, consider statin therapy, especially after the age of 55 years.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If CAC is greater than 100 Agatston units, initiate statin therapy.<xref ref-type="bibr" rid="article-29463.r26">[26]</xref></p>
          </list-item>
        </list>
        <p>Secondary ASCVD prevention: According to AHA/ACC, the high-risk category&#x000a0;is defined&#x000a0;as a history of&#x000a0;multiple major ASCVD events or one major ASCVD event&#x000a0;and multiple high-risk conditions.&#x000a0;Major ASCVD events&#x000a0;are recent acute coronary&#x000a0;syndrome (ACS) within the past 12 months,&#x000a0;MI other than the ACS, ischemic stroke, and symptomatic peripheral arterial disease (ankle-brachial index &#x0003c; 0.85 or amputation or previous revascularization). High-risk conditions&#x000a0;are&#x000a0;age &#x02265;65 years, prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG),&#x000a0;heterozygous familial hypercholesterolemia, diabetes mellitus, hypertension, chronic kidney disease, current smoking, history of heart failure, and LDL-C &#x02265;100 mg/dL.</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients &#x02264;75 years of age with clinical ASCVD, high-intensity statin therapy should be started or continued with the goal of&#x000a0;&#x02265;50% reduction in LDL-C.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients in the very high-risk category, if LDL-C&#x000a0;is &#x02265;70 mg/dL on a maximally tolerated statin therapy, clinicians should consider adding ezetimibe to statin therapy. If LDL-C&#x000a0;is still &#x02265;70 mg/dL or if non&#x02013;HDL-C &#x02265;100 mg/dL, clinicians should&#x000a0;consider adding a PCSK9 inhibitor.</p>
          </list-item>
        </list>
        <p>Homozygous familial hypercholesterolemia: Statin therapy is recommended with lipoprotein apheresis, PCSK9 inhibitors, and microsomal&#x000a0;triglyceride transfer protein (MTP) inhibitors (lomitapide).<xref ref-type="bibr" rid="article-29463.r27">[27]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>All statins are contraindicated in active liver disease.&#x000a0;Statins&#x000a0;are associated with mild-to-moderate serum aminotransferase elevations during therapy that are temporary, asymptomatic, and usually resolve without dose adjustment. Statins with minimal hepatic metabolism, such as pravastatin and rosuvastatin, are preferred in chronic liver disease.<xref ref-type="bibr" rid="article-29463.r28">[28]</xref>&#x000a0;NAFLD (nonalcoholic fatty liver disease), now also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a known risk factor for cardiovascular disease. According to American Gastroenterological Association guidelines, statins&#x000a0;benefit&#x000a0;patients with MASLD.<xref ref-type="bibr" rid="article-29463.r29">[29]</xref>&#x000a0;According to a recent study, in chronic liver disease with atherosclerotic cardiovascular disease, high statin intensity therapy is associated with a reduced risk of mortality.<xref ref-type="bibr" rid="article-29463.r30">[30]</xref>&#x000a0;The significant concern is atorvastatin in cases of decompensated cirrhosis due to an 11-fold increase in Cmax and a 16-fold increase in area under the curve. Rosuvastatin and pravastatin demonstrate pharmacokinetics resembling baseline levels due to minimal metabolization before biliary excretion in compromised liver function.<xref ref-type="bibr" rid="article-29463.r31">[31]</xref><xref ref-type="bibr" rid="article-29463.r30">[30]</xref></p>
        <p><bold>Renal impairment: </bold>Statins with minimal kidney elimination should be preferred as GFR declines. Atorvastatin appears to be the statin of choice in CKD stages 4&#x02013;5. After appropriate dose adjustments, fluvastatin may also be used for advanced CKD.<xref ref-type="bibr" rid="article-29463.r32">[32]</xref>&#x000a0;According to KDIGO (Kidney Disease Improving Global Outcomes) guidelines,&#x000a0;statin therapy is&#x000a0;recommended for adults &#x0003e;50 years with CKD stages 1 and 2. For stage 3 to stage 5 CKD (not on HD), a statin+ezetemibe combination is recommended. Statin therapy is recommended for patients between 18 to 49 years (stage 1 to 5) of age with&#x000a0;1 risk factor (known coronary artery disease, diabetes mellitus, prior ischemic stroke, the estimated 10-year incidence of coronary death, or non-fatal MI &#x0003e;10%). In&#x000a0;adult patients with dialysis-dependent CKD, statins should NOT be initiated; however, statins&#x000a0;can be continued if the patient is already&#x000a0;being administered statins&#x000a0;at the time of dialysis initiation.<xref ref-type="bibr" rid="article-29463.r33">[33]</xref>&#x000a0;A network meta-analysis demonstrated that&#x000a0;high doses of atorvastatin and fluvastatin 20&#x02009;mg/ezetimibe 10&#x02009;mg significantly prevented&#x000a0;eGFR decline&#x000a0;and proteinuria.&#x000a0;Dose adjustment is&#x000a0;required with other statins in patients with&#x000a0;stage 4 CKD (creatinine clearance &#x0003c; 30 mL/min).<xref ref-type="bibr" rid="article-29463.r34">[34]</xref></p>
        <p><bold>Pregnancy considerations: </bold>Statins are typically contraindicated in pregnancy. In 2021, the FDA advised removing the&#x000a0;contraindications of&#x000a0;statin use during pregnancy for high-risk patients. Clinicians can consider the use of statins in pregnant patients at high risk of cardiovascular events during pregnancy (patients with homozygous familial hypercholesterolemia and established cardiovascular disease).<xref ref-type="bibr" rid="article-29463.r35">[35]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The consensus is that statins should not be used during breastfeeding due to&#x000a0;disruption&#x000a0;in the infant's lipid metabolism. Other agents, such as cholestyramine, colesevelam, and colestipol, may be safe during breastfeeding.<xref ref-type="bibr" rid="article-29463.r36">[36]</xref><xref ref-type="bibr" rid="article-29463.r37">[37]</xref><xref ref-type="bibr" rid="article-29463.r38">[38]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>For patients with familial hypercholesterolemia, moderate to high-intensity statin therapy is recommended.<xref ref-type="bibr" rid="article-29463.r39">[39]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>For&#x000a0;patients &#x0003e;75 years of age, the clinician and patient should discuss the potential benefits of preventative therapies in the context of comorbidities and life expectancy.</p>
      </sec>
      <sec id="article-29463.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Statins are usually well-tolerated, with myopathy, hepatotoxicity, and diabetes mellitus being the most common adverse reactions. The incidence of myopathy is dose-dependent and may present as diffuse myalgias or otherwise unexplainable muscle tenderness or weakness with reversal upon medication discontinuation. Rhabdomyolysis is the most serious complication of statin use, but&#x000a0;the occurrence is rare.</p>
        <p>Elevated hepatic transaminases can occur.&#x000a0;This elevation is usually transient and resolves with continued therapy or after a brief therapy interruption. Patients with statin-induced hepatotoxicity have hepatocellular rather than cholestatic or mixed liver injury. The cholestatic or mixed hepatic injury appeared more predominant in patients&#x000a0;administered atorvastatin.<xref ref-type="bibr" rid="article-29463.r40">[40]</xref> The FDA no longer supports liver function tests for monitoring the use of these medications without symptoms of hepatotoxicity, such as unusual weakness or fatigue, jaundice, or dark-colored urine.<xref ref-type="bibr" rid="article-29463.r41">[41]</xref><xref ref-type="bibr" rid="article-29463.r42">[42]</xref><xref ref-type="bibr" rid="article-29463.r43">[43]</xref></p>
        <p>Statin-associated cognitive dysfunction is a rare adverse drug reaction; changing lipophilic to hydrophilic statins may resolve cognitive impairment.<xref ref-type="bibr" rid="article-29463.r44">[44]</xref>&#x000a0;Statin therapy is also associated with an increased risk of developing new-onset diabetes mellitus.<xref ref-type="bibr" rid="article-29463.r45">[45]</xref>&#x000a0;Concerns exist regarding hemorrhagic stroke with statins; however, a large cohort study&#x000a0;found no evidence that&#x000a0;HMG-Co-A-reductase inhibitors increase the risk of intracerebral hemorrhage in individuals with a history of stroke.<xref ref-type="bibr" rid="article-29463.r46">[46]</xref>&#x000a0;Statin-associated immune-mediated necrotizing myopathy is due to the development of antibodies against the HMG-CoA reductase enzyme. Symmetrical, proximal muscle weakness&#x000a0;with significantly&#x000a0;increased CPK persists for months after discontinuation of statins, which is common in statin-associated immune-mediated necrotizing myopathy.<xref ref-type="bibr" rid="article-29463.r47">[47]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Gemfibrozil-simvastatin:</bold>&#x000a0;Reduced metabolism of simvastatin&#x000a0;leads&#x000a0;to increased concentration and increased risk of&#x000a0;myopathy.&#x000a0;Avoid combination.<xref ref-type="bibr" rid="article-29463.r19">[19]</xref>&#x000a0;</p>
        <p><bold>Gemfibrozil-pravastatin:</bold> Reduced metabolism of pravastatin leads to increased concentrations and increased risk of myopathy. Avoid combination. Coadministration of a statin with a fibrate may be&#x000a0;required&#x000a0;to treat complex dyslipidemias or hypertriglyceridemia; fenofibrate is preferred&#x000a0;due to the reduced incidence of&#x000a0;drug interactions&#x000a0;compared&#x000a0;with statin-gemfibrozil therapy. (The&#x000a0;rate of gemfibrozil-associated rhabdomyolysis&#x000a0;is approximately&#x000a0;10 times higher than&#x000a0;fenofibrate).<xref ref-type="bibr" rid="article-29463.r48">[48]</xref></p>
        <p><bold>Amiodarone-lovastatin:</bold> Limit the doage of lovastatin to 40 mg daily.</p>
        <p><bold>Amiodarone-simvastatin:</bold> Limit the doage of simvastatin to 20 mg daily.</p>
        <p><bold>Conivaptan-simvastatin:</bold> Reduced metabolism of simvastatin leads to increased concentrations and increased risk of&#x000a0;myopathy.</p>
        <p><bold>Cyclosporine, tacrolimus, everolimus, sirolimus with lovastatin + pitavastatin:</bold> Avoid combination.</p>
        <p><bold>CYP3A4 mediated interactions:</bold> Atorvastatin, lovastatin, and simvastatin are primarily metabolized by CPYP3A4. Therefore, closely monitor when administered with CYP3A4 inhibitors such as amiodarone, amlodipine, ciprofloxacin, clarithromycin,&#x000a0;telithromycin, diltiazem, erythromycin, fluconazole, fluoxetine, sertraline, isoniazid, itraconazole, ketoconazole, midazolam, nefazodone, posaconazole, protease inhibitors, ranolazine, tacrolimus, ticagrelor, verapamil, and voriconazole.</p>
        <p><bold>CYP2C9 mediated interactions:</bold> Fluvastatin, and rosuvastatin is primarily metabolized by CYP2C9. Monitor for drug interactions when administered with amiodarone, etravirine, fluconazole, fluvoxamine, fluvastatin, ketoconazole, metronidazole, miconazole, sulfamethoxazole+trimethoprim, voriconazole, zafirlukast.</p>
        <p><bold>P-gp-mediated interactions:&#x000a0;</bold>Atorvastatin, lovastatin, pitavastatin, and simvastatin are substrates of&#x000a0;P-gp. Monitor for drug interactions when given with P-gp inhibitors like amiodarone, azithromycin, captopril, carvedilol, cimetidine, clarithromycin, colchicine, conivaptan, cyclosporine, diltiazem, dipyridamole, dronedarone, erythromycin, felodipine, grapefruit juice, itraconazole, ketoconazole, mefloquine, nicardipine, omeprazole, protease inhibitors, quinidine, ranolazine, sertraline, tacrolimus, verapamil. Atorvastatin, pitavastatin, lovastatin, and simvastatin are P-gp substrates and P-gp inhibitors.</p>
        <p><bold>OAT-mediated interactions:</bold> OATP1B1 is involved in statin uptake and metabolism of atorvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Therefore, monitor drug interactions when prescribed with carbamazepine, clarithromycin, erythromycin, gemfibrozil, protease inhibitors, rifampin, sildenafil, sacubitril, and telithromycin.&#x000a0;OATP1B3&#x000a0;is involved in statin uptake and metabolism of fluvastatin, pravastatin, and rosuvastatin.&#x000a0;Monitor for drug interactions when&#x000a0;prescribed clarithromycin, cyclosporine, erythromycin, rifampin, roxithromycin, rifampin, sacubitril, and telithromycin.&#x000a0;OATP&#x000a0;inhibitors&#x000a0;may increase concentrations of statins, consequently increasing the rate of adverse drug reactions,&#x000a0;including myopathy.<xref ref-type="bibr" rid="article-29463.r19">[19]</xref></p>
        <p><bold>Diltiazem + verapamil:</bold> Rhabdomyolysis&#x000a0;is reported in a patient taking atorvastatin after diltiazem.<xref ref-type="bibr" rid="article-29463.r49">[49]</xref>&#x000a0;Avoid&#x000a0;concurrent&#x000a0;administering verapamil and diltiazem with simvastatin and lovastatin as AUC increases by 3- to 8-fold.<xref ref-type="bibr" rid="article-29463.r50">[50]</xref><xref ref-type="bibr" rid="article-29463.r51">[51]</xref></p>
      </sec>
      <sec id="article-29463.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>Statins are contraindicated in active hepatic disease or unexplained persistent elevations in aminotransferase levels. Statins should typically be discontinued for most pregnant individuals. As per the FDA, healthcare professionals need to assess the therapeutic needs, especially for those at a high risk of cardiovascular events during pregnancy, such as patients with homozygous familial hypercholesterolemia or established cardiovascular disease.<xref ref-type="bibr" rid="article-29463.r12">[12]</xref><xref ref-type="bibr" rid="article-29463.r35">[35]</xref>&#x000a0;Statins are also&#x000a0;contraindicated&#x000a0;when breastfeeding because of the effects on the cholesterol pathway, as cholesterol is essential for fetal and infant synthesis of steroids and cell membrane development.<xref ref-type="bibr" rid="article-29463.r36">[36]</xref><xref ref-type="bibr" rid="article-29463.r37">[37]</xref></p>
        <p>The term statin intolerance is commonly used in medical practice. According to the guidelines of the National Lipid Association (NLA), statin intolerance is characterized as one or more adverse effects associated with statins. These adverse effects improve or resolve when the dosage is decreased or discontinued. Statin intolerance can be classified as a complete inability to tolerate any statin dosage or partial intolerance, where the patient cannot tolerate the dosage required to achieve the specific therapeutic goal.&#x000a0;Diagnosing statin intolerance requires attempting at least&#x000a0;2 statins, including one at the lowest approved daily dose. Statin intolerance is influenced by modifiable factors highlighted by NLA: hypothyroidism, avoiding alcohol and strenuous exercise, correcting vitamin D deficiency, and managing diabetes and obesity.<xref ref-type="bibr" rid="article-29463.r52">[52]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Coadministration of CYP3A4 substrate statins (atorvastatin, lovastatin, and simvastatin) with medications that are potent 3A4 inhibitors (diltiazem, erythromycin, -azoles) may result in increased serum concentrations with an increased risk of adverse effects. A reduced dose may be appropriate, or&#x000a0;a selection of an alternative statin that does not undergo metabolism via the 3A4 pathway. Administration with other drugs associated with myopathy requires caution. Simvastatin and gemfibrozil coadministration are contraindicated because of the risk of rhabdomyolysis. Dose restrictions&#x000a0;are recommended with the coadministration of gemfibrozil or other fibrates with statins, and&#x000a0;using multiple statins is not recommended.<xref ref-type="bibr" rid="article-29463.r53">[53]</xref><xref ref-type="bibr" rid="article-29463.r54">[54]</xref><xref ref-type="bibr" rid="article-29463.r55">[55]</xref></p>
      </sec>
      <sec id="article-29463.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Liver function tests should be assessed before therapy initiation, as statins are contraindicated in patients with active hepatic disease. It is unnecessary to schedule regular follow-ups of the patient's liver function&#x000a0;unless clinical symptoms of the hepatic disease&#x000a0;are apparent. Moderate-intensity therapy should result in a 30% to 50% reduction in LDL from baseline, while high-intensity therapy should result in a reduction of more than 50% from baseline. Statin medications other than atorvastatin require dose adjustment in patients with renal impairment.&#x000a0;To monitor renal status, it is important to monitor serum creatinine and creatinine clearance.<xref ref-type="bibr" rid="article-29463.r56">[56]</xref><xref ref-type="bibr" rid="article-29463.r57">[57]</xref><xref ref-type="bibr" rid="article-29463.r58">[58]</xref></p>
        <p>Close monitoring of creatine kinase (CK) and statins is recommended when colchicine is used. Patients on&#x000a0;high-intensity atorvastatin may be at increased risk of digoxin toxicity, and&#x000a0;monitoring for digoxin toxicity is suggested.&#x000a0;LDL-C response should be monitored to adjust the dose and intensity of statin therapy. According to AHA, fasting lipid panel&#x000a0;monitoring should be measured at baseline and 4 to 12 weeks after statin initiation or dose adjustment. Follow-up monitoring&#x000a0;is preferred every 3 to 12 months.<xref ref-type="bibr" rid="article-29463.r19">[19]</xref></p>
      </sec>
      <sec id="article-29463.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Statins are now well-established drugs with proven effectiveness in reducing adverse cardiovascular and cerebrovascular events. Rhabdomyolysis presents with severe muscle pain, weakness, and dark urine due to myoglobinuria, leading to acute kidney injury. Laboratory&#x000a0;tests reveal elevated serum levels of&#x000a0;CK and myoglobin, with myoglobin breakdown products in the urine, contributing to dark or tea-colored urine.<xref ref-type="bibr" rid="article-29463.r59">[59]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No antidote is available to reverse the myopathy or rhabdomyolysis caused by statins. The general treatment is supportive and comprises immediate discontinuation of the offending drug. Aggressive fluid management is the cornerstone of therapy.<xref ref-type="bibr" rid="article-29463.r60">[60]</xref>&#x000a0;The urine output requires monitoring, and a Foley catheter insertion may be necessary. Other supportive measures include correcting electrolyte disturbances and monitoring the patient with continuous&#x000a0;EKG monitoring if hyperkalemia is present. Insulin-dextrose treatment (IDT) is a first-line treatment for moderate (K+ 6 mmol/L to 7&#x000a0;mmol/L) to severe hyperkalemia (K+&#x02009;&#x0003e;&#x02009; 7&#x000a0;mmol/L).<xref ref-type="bibr" rid="article-29463.r61">[61]</xref></p>
        <p>All patients need continual follow-ups to monitor for hyperkalemia and acute kidney injury. The patient may be discharged when electrolytes return to normal and no renal dysfunction is apparent. The decision to restart a statin requires good clinical judgment. Clinicians should avoid concomitant fibrates and use only the lowest dose of another statin. The patient should be monitored for muscle pain and routine urine and blood tests to ensure muscle breakdown is not recurring. The statin-associated autoimmune myopathy requires aggressive immunosuppression with steroids, methotrexate, and intravenous immunoglobulin (IVIG) or rituximab.<xref ref-type="bibr" rid="article-29463.r47">[47]</xref></p>
      </sec>
      <sec id="article-29463.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Statin therapy requires an interprofessional healthcare team that includes clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists. When the patient&#x000a0;is prescribed a statin, the nurse and pharmacist should educate the patient on the dose and&#x000a0;adverse&#x000a0;effects of the drugs. The pharmacist must regularly check the patient's list of medications to ensure safety and prevent polypharmacy interactions. Nursing staff should verify medication compliance, ask about any new symptoms that may have links to statin use, counsel the patient on administration, and inform the prescriber of any concerns.</p>
        <p>Further, clinicians should monitor liver function because&#x000a0;of the risk of transaminase elevations. A meta-analysis suggests that statin therapy can reduce cardiovascular adverse events in coronary artery spasms. The association between the two was stronger in Japanese patients and those who were followed up for more than&#x000a0;4 years.<xref ref-type="bibr" rid="article-29463.r62">[62]</xref></p>
        <p>Statin therapy correlates with an increased risk of diabetes, with the first notable JUPITER trial published in 2008.<xref ref-type="bibr" rid="article-29463.r63">[63]</xref>&#x000a0;A meta-analysis study involving 91140 patients published in 2014 showed a 9% increase in the likelihood of developing diabetes mellitus.<xref ref-type="bibr" rid="article-29463.r64">[64]</xref>&#x000a0;Studies have found that pitavastatin&#x000a0;should be the drug of choice in pre-diabetic patients to reduce the risk of developing diabetes. The REAL-CAD trial published in 2018 found that a higher dose of pitavastatin significantly&#x000a0;reduced cardiovascular events in Japanese patients with coronary artery disease compared to a lower dose of pitavastatin.<xref ref-type="bibr" rid="article-29463.r65">[65]</xref>&#x000a0;A recent updated meta-analysis showed that coenzyme Q10 supplementation reduced statin-associated muscle symptoms.<xref ref-type="bibr" rid="article-29463.r66">[66]</xref>&#x000a0;Clinicians should consider CoQ10 supplementation before discontinuing statin medication.</p>
        <p>Clinical trials&#x000a0;have&#x000a0;shown that statins effectively lower cholesterol and the risk of adverse cardiac events.&#x000a0;The ALLHAT-LLT trial found no benefit in primary prevention&#x000a0;in older adults aged above 75 with statin therapy and hyperlipidemia.<xref ref-type="bibr" rid="article-29463.r58">[58]</xref>&#x000a0;Statin therapy should still resume in older patients with a history of coronary artery disease, stroke, and diabetes mellitus. A systemic review of&#x000a0;35 studies&#x000a0;(925,171 patients) demonstrated that&#x000a0;pharmacist-led medication reconciliation, patient education, and interprofessional&#x000a0;collaboration between pharmacists, primary care clinicians, and cardiologists&#x000a0;improves patient compliance with lipid-lowering medications, including statins.<xref ref-type="bibr" rid="article-29463.r67">[67]</xref></p>
      </sec>
      <sec id="article-29463.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29463&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29463">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29463/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29463">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29463.s11">
        <title>References</title>
        <ref id="article-29463.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Malley</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spacek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buelt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Vagichev</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ballard-Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Logan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Downs</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.</article-title>
            <source>Ann Intern Med</source>
            <year>2020</year>
            <month>Nov</month>
            <day>17</day>
            <volume>173</volume>
            <issue>10</issue>
            <fpage>822</fpage>
            <page-range>822-829</page-range>
            <pub-id pub-id-type="pmid">32956597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strilchuk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tocci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fogacci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cicero</surname>
                <given-names>AFG</given-names>
              </name>
            </person-group>
            <article-title>An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-539</page-range>
            <pub-id pub-id-type="pmid">32036729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koopal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marais</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.</article-title>
            <source>Curr Opin Endocrinol Diabetes Obes</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-139</page-range>
            <pub-id pub-id-type="pmid">28098593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rygiel</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hypertriglyceridemia - Common Causes, Prevention and Treatment Strategies.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>14</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">29366425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rosendael</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>van den Hoogen</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Gianni</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tantawy</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Andreini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Al-Mallah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Budoff</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cademartiri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chinnaiyan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Ara&#x000fa;jo Gon&#x000e7;alves</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hadamitzky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leipsic</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maffei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pontone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Chun</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Virmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Samady</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Narula</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blankstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition.</article-title>
            <source>JAMA Cardiol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>1257</fpage>
            <page-range>1257-1266</page-range>
            <pub-id pub-id-type="pmid">34406326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jun</month>
            <day>18</day>
            <volume>139</volume>
            <issue>25</issue>
            <fpage>e1082</fpage>
            <page-range>e1082-e1143</page-range>
            <pub-id pub-id-type="pmid">30586774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amarenco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tonkin</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Statins for stroke prevention: disappointment and hope.</article-title>
            <source>Circulation</source>
            <year>2004</year>
            <month>Jun</month>
            <day>15</day>
            <volume>109</volume>
            <issue>23 Suppl 1</issue>
            <fpage>III44</fpage>
            <page-range>III44-9</page-range>
            <pub-id pub-id-type="pmid">15198966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luirink</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kusters</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hof</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Groothoff</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>de Groot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJP</given-names>
              </name>
              <name>
                <surname>Hutten</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>17</day>
            <volume>381</volume>
            <issue>16</issue>
            <fpage>1547</fpage>
            <page-range>1547-1556</page-range>
            <pub-id pub-id-type="pmid">31618540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGowan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hosseini Dehkordi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Duell</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2019</year>
            <month>Dec</month>
            <day>17</day>
            <volume>8</volume>
            <issue>24</issue>
            <fpage>e013225</fpage>
            <pub-id pub-id-type="pmid">31838973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rinella</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Abdelmalek</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barb</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.</article-title>
            <source>Hepatology</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>1797</fpage>
            <page-range>1797-1835</page-range>
            <pub-id pub-id-type="pmid">36727674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asleh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Briasoulis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Boilson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Adigun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maltais</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kushwaha</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.</article-title>
            <source>ESC Heart Fail</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>1118</fpage>
            <page-range>1118-1129</page-range>
            <pub-id pub-id-type="pmid">30019530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kolte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>LoFaso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahtta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Taqueti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MS</given-names>
              </name>
              <collab>Peer Review Committee Members</collab>
            </person-group>
            <article-title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2023</year>
            <month>Aug</month>
            <day>29</day>
            <volume>148</volume>
            <issue>9</issue>
            <fpage>e9</fpage>
            <page-range>e9-e119</page-range>
            <pub-id pub-id-type="pmid">37471501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirtori</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of statins.</article-title>
            <source>Pharmacol Res</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>88</volume>
            <fpage>3</fpage>
            <page-range>3-11</page-range>
            <pub-id pub-id-type="pmid">24657242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavalipati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramakrishan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vasnawala</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pleiotropic effects of statins.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>554</fpage>
            <page-range>554-62</page-range>
            <pub-id pub-id-type="pmid">26425463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Climent</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benaiges</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pedro-Botet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hydrophilic or Lipophilic Statins?</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>687585</fpage>
            <pub-id pub-id-type="pmid">34095267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filppula</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hirvensalo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parviainen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ivaska</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nnberg</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Viinam&#x000e4;ki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kurkela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niemi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>49</volume>
            <issue>8</issue>
            <fpage>658</fpage>
            <page-range>658-667</page-range>
            <pub-id pub-id-type="pmid">34045219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egom</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Hafeez</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Biochemistry of Statins.</article-title>
            <source>Adv Clin Chem</source>
            <year>2016</year>
            <volume>73</volume>
            <fpage>127</fpage>
            <page-range>127-68</page-range>
            <pub-id pub-id-type="pmid">26975972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wessler</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Grip</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Mendell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>The P-glycoprotein transport system and cardiovascular drugs.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jun</month>
            <day>25</day>
            <volume>61</volume>
            <issue>25</issue>
            <fpage>2495</fpage>
            <page-range>2495-502</page-range>
            <pub-id pub-id-type="pmid">23563132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiggins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Sneed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Lanfear</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PB</given-names>
              </name>
              <collab>American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology</collab>
            </person-group>
            <article-title>Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Nov</month>
            <day>22</day>
            <volume>134</volume>
            <issue>21</issue>
            <fpage>e468</fpage>
            <page-range>e468-e495</page-range>
            <pub-id pub-id-type="pmid">27754879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Greenland</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Statin Usage in Primary Prevention-Comparing the USPSTF Recommendations With the AHA/ACC/Multisociety Guidelines.</article-title>
            <source>JAMA Cardiol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>01</day>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>997</fpage>
            <page-range>997-999</page-range>
            <pub-id pub-id-type="pmid">35998005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task&#x000a0;Force&#x000a0;on&#x000a0;Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>25</day>
            <volume>73</volume>
            <issue>24</issue>
            <fpage>e285</fpage>
            <page-range>e285-e350</page-range>
            <pub-id pub-id-type="pmid">30423393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jun</month>
            <day>18</day>
            <volume>139</volume>
            <issue>25</issue>
            <fpage>e1046</fpage>
            <page-range>e1046-e1081</page-range>
            <pub-id pub-id-type="pmid">30565953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamal</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Effects of single-dose morning and evening administration of pravastatin on antioxidant markers in cholesterol-fed rabbits.</article-title>
            <source>J Exp Pharmacol</source>
            <year>2011</year>
            <volume>3</volume>
            <fpage>51</fpage>
            <page-range>51-8</page-range>
            <pub-id pub-id-type="pmid">27186110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colantonio</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levitan</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Safford</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Apr</month>
            <day>09</day>
            <volume>311</volume>
            <issue>14</issue>
            <fpage>1406</fpage>
            <page-range>1406-15</page-range>
            <pub-id pub-id-type="pmid">24682252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buroker</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Himmelfarb</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Michos</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Miedema</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ziaeian</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Sep</month>
            <day>10</day>
            <volume>140</volume>
            <issue>11</issue>
            <fpage>e596</fpage>
            <page-range>e596-e646</page-range>
            <pub-id pub-id-type="pmid">30879355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahabadi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>M&#x000f6;hlenkamp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lehmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>K&#x000e4;lsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dykun</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pundt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moebus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>J&#x000f6;ckel</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Erbel</surname>
                <given-names>R</given-names>
              </name>
              <collab>Heinz Nixdorf Recall Study Investigators</collab>
            </person-group>
            <article-title>CAC Score Improves Coronary and CV&#x000a0;Risk&#x000a0;Assessment Above Statin Indication&#x000a0;by ESC and AHA/ACC Primary&#x000a0;Prevention&#x000a0;Guidelines.</article-title>
            <source>JACC Cardiovasc Imaging</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-153</page-range>
            <pub-id pub-id-type="pmid">27665163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nohara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Daida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dobashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Minamino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harada-Shiba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Homozygous Familial Hypercholesterolemia.</article-title>
            <source>J Atheroscler Thromb</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>665</fpage>
            <page-range>665-678</page-range>
            <pub-id pub-id-type="pmid">33867421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Statins</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Serper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khungar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Firpi-Morell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barritt</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gazis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mospan</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>458</fpage>
            <page-range>458-460.e4</page-range>
            <pub-id pub-id-type="pmid">33775894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sinn</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>High-Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population-Based Cohort Study.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2023</year>
            <month>Apr</month>
            <day>18</day>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>e028310</fpage>
            <pub-id pub-id-type="pmid">37066797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Use of Statins in Patients With and Without Liver Disease.</article-title>
            <source>Clin Liver Dis (Hoboken)</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-45</page-range>
            <pub-id pub-id-type="pmid">32104577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalaitzidis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The role of statins in chronic kidney disease.</article-title>
            <source>Am J Nephrol</source>
            <year>2011</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-202</page-range>
            <pub-id pub-id-type="pmid">21791915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Titze</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nadal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schlieper</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baid-Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krane</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kronenberg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eckardt</surname>
                <given-names>KU</given-names>
              </name>
            </person-group>
            <article-title>Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates.</article-title>
            <source>Kidney Int</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>88</volume>
            <issue>6</issue>
            <fpage>1411</fpage>
            <page-range>1411-1418</page-range>
            <pub-id pub-id-type="pmid">26331409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esmeijer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>de Fijter</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dekker</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Hoogeveen</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Nov</month>
            <day>12</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>16632</fpage>
            <pub-id pub-id-type="pmid">31719617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aschenbrenner</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Statins No Longer Contraindicated in Pregnancy.</article-title>
            <source>Am J Nurs</source>
            <year>2021</year>
            <month>Nov</month>
            <day>01</day>
            <volume>121</volume>
            <issue>11</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">34673690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <chapter-title>Atorvastatin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <chapter-title>Rosuvastatin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Simvastatin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Besseling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Huijgen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJP</given-names>
              </name>
              <name>
                <surname>Hutten</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause&#x000a0;Mortality.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jul</month>
            <day>19</day>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <page-range>252-260</page-range>
            <pub-id pub-id-type="pmid">27417002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Statin Toxicity.</article-title>
            <source>Circ Res</source>
            <year>2019</year>
            <month>Jan</month>
            <day>18</day>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>328</fpage>
            <page-range>328-350</page-range>
            <pub-id pub-id-type="pmid">30653440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Statin Intolerance.</article-title>
            <source>Rev Cardiovasc Med</source>
            <year>2018</year>
            <volume>19</volume>
            <issue>S1</issue>
            <fpage>S9</fpage>
            <page-range>S9-S19</page-range>
            <pub-id pub-id-type="pmid">30207553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caughey</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Gabb</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ronson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beukelman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Limaye</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population.</article-title>
            <source>JAMA Intern Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>178</volume>
            <issue>9</issue>
            <fpage>1224</fpage>
            <page-range>1224-1229</page-range>
            <pub-id pub-id-type="pmid">30073275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Abdullahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rattle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Snedden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Junckerstorff</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Retrospective evaluation of statin prescription in the elderly.</article-title>
            <source>Intern Med J</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>1463</fpage>
            <page-range>1463-1471</page-range>
            <pub-id pub-id-type="pmid">29869449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rojas-Fernandez</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.</article-title>
            <source>Ann Pharmacother</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-57</page-range>
            <pub-id pub-id-type="pmid">22474137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emberson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danesh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacMahon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Preiss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ridker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sandercock</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smeeth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Interpretation of the evidence for the efficacy and safety of statin therapy.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Nov</month>
            <day>19</day>
            <volume>388</volume>
            <issue>10059</issue>
            <fpage>2532</fpage>
            <page-range>2532-2561</page-range>
            <pub-id pub-id-type="pmid">27616593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribe</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Prior</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lietzen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Brynningsen</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Fenger-Gr&#x000f8;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Statins and Risk of Intracerebral Hemorrhage in Individuals With a History of Stroke.</article-title>
            <source>Stroke</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>1111</fpage>
            <page-range>1111-1119</page-range>
            <pub-id pub-id-type="pmid">32114928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiniakou</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Statin-Associated Autoimmune Myopathy: Current Perspectives.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2020</year>
            <volume>16</volume>
            <fpage>483</fpage>
            <page-range>483-492</page-range>
            <pub-id pub-id-type="pmid">32581543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alsheikh-Ali</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kuvin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Karas</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Risk of adverse events with fibrates.</article-title>
            <source>Am J Cardiol</source>
            <year>2004</year>
            <month>Oct</month>
            <day>01</day>
            <volume>94</volume>
            <issue>7</issue>
            <fpage>935</fpage>
            <page-range>935-8</page-range>
            <pub-id pub-id-type="pmid">15464682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehelepola</surname>
                <given-names>NDB</given-names>
              </name>
              <name>
                <surname>Sathkumara</surname>
                <given-names>SMBY</given-names>
              </name>
              <name>
                <surname>Bandara</surname>
                <given-names>HMPAGS</given-names>
              </name>
              <name>
                <surname>Kalupahana</surname>
                <given-names>KLR</given-names>
              </name>
            </person-group>
            <article-title>Atorvastatin-Diltiazem Combination Induced Rhabdomyolysis Leading to Diagnosis of Hypothyroidism.</article-title>
            <source>Case Rep Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>8383251</fpage>
            <pub-id pub-id-type="pmid">28487744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>e2487</fpage>
            <pub-id pub-id-type="pmid">26765458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis with concurrent atorvastatin and diltiazem.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1546</fpage>
            <page-range>1546-9</page-range>
            <pub-id pub-id-type="pmid">12243603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheeley</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Agarwala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ravilla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ciffone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.</article-title>
            <source>J Clin Lipidol</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-375</page-range>
            <pub-id pub-id-type="pmid">35718660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hullikunte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simmonds</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Improving the Prescribing Gap For Guideline Recommended Medications Post Myocardial Infarction.</article-title>
            <source>Heart Lung Circ</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-262</page-range>
            <pub-id pub-id-type="pmid">29523466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gonzales</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vittinghoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Fleischmann</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Auerbach</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Appropriate Reconciliation of Cardiovascular Medications After Elective Surgery and Postdischarge Acute Hospital and Ambulatory Visits.</article-title>
            <source>J Hosp Med</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>723</fpage>
            <page-range>723-730</page-range>
            <pub-id pub-id-type="pmid">28914276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Borden</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Statin use in outpatients with obstructive coronary artery disease.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Nov</month>
            <day>29</day>
            <volume>124</volume>
            <issue>22</issue>
            <fpage>2405</fpage>
            <page-range>2405-10</page-range>
            <pub-id pub-id-type="pmid">22064595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coste</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Billionnet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudnichi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pouchot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dray-Spira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giral</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zureik</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France.</article-title>
            <source>Eur J Prev Cardiol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-521</page-range>
            <pub-id pub-id-type="pmid">29799296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moctezuma-Vel&#x000e1;zquez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abraldes</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Montano-Loza</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis.</article-title>
            <source>Curr Treat Options Gastroenterol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>226</fpage>
            <page-range>226-240</page-range>
            <pub-id pub-id-type="pmid">29572618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Sutin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Piller</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Pervin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pressel</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Blaum</surname>
                <given-names>CS</given-names>
              </name>
              <collab>ALLHAT Collaborative Research Group</collab>
            </person-group>
            <article-title>Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>177</volume>
            <issue>7</issue>
            <fpage>955</fpage>
            <page-range>955-965</page-range>
            <pub-id pub-id-type="pmid">28531241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robles</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Statin-induced rhabdomyolysis: a comprehensive review of case reports.</article-title>
            <source>Physiother Can</source>
            <year>2014</year>
            <season>Spring</season>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-32</page-range>
            <pub-id pub-id-type="pmid">24799748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabral</surname>
                <given-names>BMI</given-names>
              </name>
              <name>
                <surname>Edding</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Portocarrero</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis.</article-title>
            <source>Dis Mon</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>66</volume>
            <issue>8</issue>
            <fpage>101015</fpage>
            <pub-id pub-id-type="pmid">32532456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crnobrnja</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Metlapalli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Govinna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>AKH</given-names>
              </name>
            </person-group>
            <article-title>The Association of Insulin-dextrose Treatment with Hypoglycemia in Patients with Hyperkalemia.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Dec</month>
            <day>16</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>22044</fpage>
            <pub-id pub-id-type="pmid">33328554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2023</year>
            <volume>2023</volume>
            <fpage>8807278</fpage>
            <pub-id pub-id-type="pmid">37151221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ridker</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Danielson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Genest</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gotto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lorenzatti</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>MacFadyen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willerson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>JUPITER Study Group</collab>
            </person-group>
            <article-title>Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Nov</month>
            <day>20</day>
            <volume>359</volume>
            <issue>21</issue>
            <fpage>2195</fpage>
            <page-range>2195-207</page-range>
            <pub-id pub-id-type="pmid">18997196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chogtu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Magazine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bairy</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Statin use and risk of diabetes mellitus.</article-title>
            <source>World J Diabetes</source>
            <year>2015</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <page-range>352-7</page-range>
            <pub-id pub-id-type="pmid">25789118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taguchi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iimuro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amiya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sakuma</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hibi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hiro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hokimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Otsuji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Urabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Terayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Toyoda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ohtsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Daida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shimokawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuzaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>May</month>
            <day>08</day>
            <volume>137</volume>
            <issue>19</issue>
            <fpage>1997</fpage>
            <page-range>1997-2009</page-range>
            <pub-id pub-id-type="pmid">29735587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>DZ</given-names>
              </name>
            </person-group>
            <article-title>Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Oct</month>
            <day>02</day>
            <volume>7</volume>
            <issue>19</issue>
            <fpage>e009835</fpage>
            <pub-id pub-id-type="pmid">30371340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29463.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Driel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Morledge</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ulep</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaffer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deichmann</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Interventions to improve adherence to lipid-lowering medication.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Dec</month>
            <day>21</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD004371</fpage>
            <pub-id pub-id-type="pmid">28000212</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
